{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:42:05Z","timestamp":1792449725934,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":94,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Key Science and Technology Program of Henan Province","award":["232102310394"],"award-info":[{"award-number":["232102310394"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Breast cancer (BRCA) remains a leading cause of cancer-related mortality worldwide, necessitating the identification of novel biomarkers and therapeutic targets to overcome challenges such as treatment resistance and metastasis. In this study, we systematically characterized the multi-omic landscape of G1 to S phase transition protein 1 (GSPT1) in BRCA. Integrative bioinformatic analysis of public datasets revealed that GSPT1 mRNA and protein levels are significantly upregulated in BRCA across all clinical stages and molecular subtypes. To validate these findings, we performed immunohistochemical (IHC) staining on representative patient-derived tissue samples, which, complemented by transcriptomic analysis of diverse cell lines, confirmed this upregulation. High GSPT1 expression and its prevalent genomic alterations identified in public cohorts\u2014particularly gene amplification observed in approximately 14% of cases\u2014were strongly correlated with poor clinical outcomes, including diminished overall survival (OS), relapse-free survival (RFS), and distant metastasis-free survival (DMFS). Functional enrichment analyses indicated that GSPT1 expression is strongly associated with pathways critical for tumorigenesis, such as the cell cycle, DNA replication, and mitotic spindle organization. Furthermore, dependency analysis via the DepMap database and our experimental validation demonstrated that BRCA cells are highly dependent on GSPT1 for survival. Collectively, our findings further substantiate GSPT1 as a robust prognostic biomarker and provide translational evidence supporting its feasibility as a molecular glue-targetable vulnerability for precision oncology in BRCA.<\/jats:p>","DOI":"10.1038\/s41598-026-61699-w","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T21:23:08Z","timestamp":1784409788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unveiling GSPT1 as a crucial prognostic biomarker and therapeutic vulnerability in breast cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Huafei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanlin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"key":"61699_CR1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/cac2.12358","volume":"42","author":"RX Hong","year":"2022","unstructured":"Hong, R. X. & Xu, B. H. Breast cancer: An up-to-date review and future perspectives. Cancer Commun. 42, 913\u2013936 (2022).","journal-title":"Cancer Commun."},{"key":"61699_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"61699_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"61699_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong, X. et al. Breast cancer: Pathogenesis and treatments. Signal Transduct. Target. Ther. 10, 49 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"61699_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2021.0459","volume":"83","author":"C Katsura","year":"2022","unstructured":"Katsura, C., Ogunmwonyi, I., Kankam, H. K. N. & Saha, S. Breast cancer: presentation, investigation and management. Br. J. Hosp. Med. 83, 1\u201321 (2022).","journal-title":"Br. J. Hosp. Med."},{"key":"61699_CR6","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","volume":"32","author":"HJ Burstein","year":"2021","unstructured":"Burstein, H. J. et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann. Oncol. 32, 1216\u20131235 (2021).","journal-title":"Ann. Oncol."},{"key":"61699_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","volume":"21","author":"L Morrison","year":"2024","unstructured":"Morrison, L., Loibl, S. & Turner, N. C. The CDK4\/6 inhibitor revolution: a game-changing era for breast cancer treatment. Nat. Rev. Clin. Oncol. 21, 89\u2013105 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"61699_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13058-021-01459-y","volume":"23","author":"E Ferraro","year":"2021","unstructured":"Ferraro, E., Drago, J. Z. & Modi, S. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: State of the art and future directions. Breast Cancer Res. 2384. (2021).","journal-title":"Breast Cancer Res."},{"key":"61699_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188593","volume":"1876","author":"YX Zhu","year":"2021","unstructured":"Zhu, Y. X. et al. Progress and challenges of immunotherapy in triple-negative breast cancer. Biochim. Biophys. Acta (BBA) - Rev. Cancer 1876, 188593 (2021).","journal-title":"Biochim. Biophys. Acta (BBA) - Rev. Cancer"},{"key":"61699_CR10","doi-asserted-by":"publisher","first-page":"4678632","DOI":"10.1155\/2020\/3928976","volume":"2020","author":"L Tagliaferri","year":"2020","unstructured":"Tagliaferri, L. et al. Could a personalized strategy using accelerated partial breast irradiation be an advantage for elderly patients? A systematic review of the literature and multidisciplinary opinion. J. Oncol. 2020, 4678632 (2020).","journal-title":"J. Oncol."},{"key":"61699_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41422-020-0375-9","volume":"31","author":"YZ Jiang","year":"2021","unstructured":"Jiang, Y. Z. et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell. Res. 31, 178\u2013186 (2021).","journal-title":"Cell. Res."},{"key":"61699_CR12","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia, A. et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N. Engl. J. Med. 384, 1529\u20131541 (2021).","journal-title":"N. Engl. J. Med."},{"key":"61699_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.annonc.2020.10.471","volume":"32","author":"PA Fasching","year":"2021","unstructured":"Fasching, P. A. et al. Neoadjuvant paclitaxel\/olaparib in comparison to paclitaxel\/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann. Oncol. 32, 49\u201357 (2021).","journal-title":"Ann. Oncol."},{"key":"61699_CR14","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.cell.2024.02.009","volume":"187","author":"C Swanton","year":"2024","unstructured":"Swanton, C. et al. Embracing cancer complexity: hallmarks of systemic disease. Cell 187, 1589\u20131616 (2024).","journal-title":"Cell"},{"key":"61699_CR15","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346\u2013352 (2012).","journal-title":"Nature"},{"key":"61699_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202511789","volume":"12","author":"QQ Lin","year":"2025","unstructured":"Lin, Q. Q. et al. Cancer biology of GSPT1: Mechanisms and targeted therapy opportunities of molecular glue degraders. Adv. Sci. 12, 2417238 (2025).","journal-title":"Adv. Sci."},{"key":"61699_CR17","doi-asserted-by":"crossref","first-page":"118025","DOI":"10.1016\/j.bmc.2024.118025","volume":"118","author":"C Liu","year":"2025","unstructured":"Liu, C., Peng, H. K., Chen, P. & Jiang, B. GSPT1 degraders: research progress, development strategies and challenges. Bioorg. Med. Chem. 118, 118025 (2025).","journal-title":"Bioorg. Med. Chem."},{"key":"61699_CR18","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/wrna.1133","volume":"3","author":"S Hoshino","year":"2012","unstructured":"Hoshino, S. Mechanism of the initiation of mRNA decay: role of eRF3 family G proteins. Wiley Interdiscip Rev. RNA. 3, 743\u2013757 (2012).","journal-title":"Wiley Interdiscip Rev. RNA"},{"key":"61699_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/cm.10040","volume":"52","author":"IA Valouev","year":"2002","unstructured":"Valouev, I. A., Kushnirov, V. V. & Ter-Avanesyan, M. D. Yeast polypeptide chain release factors eRF1 and eRF3 are involved in cytoskeleton organization and cell cycle regulation. Cell Motil. Cytoskeleton 52, 161\u2013173 (2002).","journal-title":"Cell Motil. Cytoskeleton"},{"key":"61699_CR20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1182\/blood.2022017813","volume":"142","author":"YC Chang","year":"2023","unstructured":"Chang, Y. C. et al. The orally bioavailable GSPT1\/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemia. Blood 142, 629\u2013642 (2023).","journal-title":"Blood"},{"key":"61699_CR21","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/emboj.2008.17","volume":"27","author":"PV Ivanov","year":"2008","unstructured":"Ivanov, P. V. et al. Interactions between UPF1, eRFs, PABP and the exon junction complex suggest an integrated model for mammalian NMD pathways. EMBO J. 27, 736\u2013747 (2008).","journal-title":"EMBO J."},{"key":"61699_CR22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1242\/jcs.181008","volume":"129","author":"T Kurosaki","year":"2016","unstructured":"Kurosaki, T. & Maquat, L. E. Nonsense-mediated mRNA decay in humans at a glance. J. Cell. Sci. 129, 461\u2013467 (2016).","journal-title":"J. Cell. Sci."},{"key":"61699_CR23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s11596-022-2665-6","volume":"43","author":"QX Yi","year":"2023","unstructured":"Yi, Q. X. et al. GSPT1 functions as a tumor promoter in human liver cancer. Curr. Med. Sci. 43, 104\u2013114 (2023).","journal-title":"Curr. Med. Sci."},{"key":"61699_CR24","doi-asserted-by":"publisher","first-page":"Abstract3904","DOI":"10.1182\/blood-2019-127892","volume":"134","author":"A Lopez-Girona","year":"2019","unstructured":"Lopez-Girona, A. et al. CC-90009, a novel cereblon E3 ligase modulator, targets GSPT1 for degradation to induce potent tumoricidal activity against acute myeloid leukemia (AML). Blood 134, Abstract3904 (2019).","journal-title":"Blood"},{"key":"61699_CR25","doi-asserted-by":"publisher","first-page":"AbstractB158","DOI":"10.1158\/1535-7163.TARG-21-LBA004","volume":"20","author":"G Gavory","year":"2021","unstructured":"Gavory, G. et al. Identification of GSPT1-directed molecular glue degrader (MGD) for the treatment of Myc-driven breast cancer. Mol. Cancer Ther. 20, AbstractB158 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"61699_CR26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature18611","volume":"535","author":"ME Matyskiela","year":"2016","unstructured":"Matyskiela, M. E. et al. A novel cereblon modulator recruits GSPT1 to the CRL4 ubiquitin ligase. Nature 535, 252\u2013256 (2016).","journal-title":"Nature"},{"key":"61699_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.107000","author":"DD Zhang","year":"2024","unstructured":"Zhang, D. D., Lin, P. & Lin, J. Molecular glues targeting GSPT1 in cancers: A potent therapy. Bioorg. Chem. https:\/\/doi.org\/10.1016\/j.bioorg.2023.107000 (2024).","journal-title":"Bioorg. Chem."},{"key":"61699_CR28","doi-asserted-by":"publisher","first-page":"Abstract3423","DOI":"10.1158\/1538-7445.AM2022-3929","volume":"82","author":"G Gavory","year":"2022","unstructured":"Gavory, G. et al. Identification of MRT-2359 a potent, selective and orally bioavailable GSPT1-directed molecular glue degrader (MGD) for the treatment of cancers with Myc-induced translational addiction. Cancer Res. 82, Abstract3423 (2022).","journal-title":"Cancer Res."},{"key":"61699_CR29","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1021\/acs.jmedchem.0c01489","volume":"64","author":"JD Hansen","year":"2021","unstructured":"Hansen, J. D. et al. CC-90009: A cereblon E3 ligase modulating drug that promotes selective degradation of GSPT1 for the treatment of acute myeloid leukemia. J. Med. Chem. 64, 1835\u20131843 (2021).","journal-title":"J. Med. Chem."},{"key":"61699_CR30","doi-asserted-by":"publisher","first-page":"Abstract 232","DOI":"10.1182\/blood-2019-123966","volume":"134","author":"GL Uy","year":"2019","unstructured":"Uy, G. L. et al. Clinical activity of CC-90009, a cereblon E3 ligase modulator and first-in-class GSPT1 degrader, as a single agent in patients with relapsed or refractory acute myeloid leukemia (R\/R AML): first results from a phase I dose-finding study. Blood 134, Abstract 232 (2019).","journal-title":"Blood"},{"key":"61699_CR31","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2751918\/v1","author":"LH Xu","year":"2023","unstructured":"Xu, L. H. et al. GSPT1 promotes the proliferation, migration, and invasion of breast cancer cells. Res. Square. https:\/\/doi.org\/10.21203\/rs.3.rs-2751918\/v1 (2023).","journal-title":"Res. Square"},{"key":"61699_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202511789","volume":"12","author":"QQ Lin","year":"2025","unstructured":"Lin, Q. Q. et al. Cancer biology of GSPT1: Mechanisms and targeted therapy opportunities of molecular glue degraders. Adv. Sci. 12, e11789 (2025).","journal-title":"Adv. Sci."},{"key":"61699_CR33","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"XS Liu","year":"2020","unstructured":"Liu, X. S. et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 48, W509\u2013W514 (2020).","journal-title":"Nucleic Acids Res."},{"key":"61699_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","volume":"25","author":"DS Chandrashekar","year":"2022","unstructured":"Chandrashekar, D. S. et al. UALCAN: an update to the integrated cancer data analysis platform. Neoplasia 25, 18\u201327 (2022).","journal-title":"Neoplasia"},{"key":"61699_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41374-8","author":"F Chen","year":"2023","unstructured":"Chen, F., Zhang, Y., Chandrashekar, D. S., Varambally, S. & Creighton, C. J. Global impact of somatic structural variation on the cancer proteome. Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-023-41374-8 (2023).","journal-title":"Nat. Commun."},{"key":"61699_CR36","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/ng.3984","volume":"49","author":"RM Meyers","year":"2017","unstructured":"Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779\u20131784 (2017).","journal-title":"Nat. Genet."},{"key":"61699_CR37","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.7717\/peerj-cs.67","volume":"2","author":"J Anaya","year":"2016","unstructured":"Anaya, J. OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. PeerJ Comput. Sci. 2, e67 (2016).","journal-title":"PeerJ Comput. Sci."},{"key":"61699_CR38","doi-asserted-by":"publisher","first-page":"5734","DOI":"10.1111\/bph.70215","volume":"182","author":"M Posta","year":"2025","unstructured":"Posta, M. & Gy\u0151rffy, B. Pathway-level mutational signatures predict breast cancer outcomes and reveal therapeutic targets. Br. J. Pharmacol. 182, 5734\u20135747 (2025).","journal-title":"Br. J. Pharmacol."},{"key":"61699_CR39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov"},{"key":"61699_CR40","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M. et al. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 53, D672\u2013D677 (2025).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61699-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61699-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61699-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:26:23Z","timestamp":1792448783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61699-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["61699"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-61699-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In our study, all procedures performed involving human tissue samples were in accordance with the ethical standards of the institutional research committee of the First Affiliated Hospital of Zhengzhou University (Approval No: 2025-KY-2208-001). Informed consent was obtained from all patients prior to the collection of clinical tissue samples. The research was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and complied with all applicable institutional, national, and international guidelines and regulations for research involving human subjects.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"32883"}}